14 Jan 2008 - UK-based peptide synthesis technology company, Activotec, has just completed a significant funding round to enable it to further accelerate the growth of its business. Reflecting the solid growth achieved by the company over the last few years the new funding money was raised quickly through a syndicate comprised of Activotec's existing shareholders.
Activotec chief executive, Chris Littlewood, commented: "The funds will be invested in expanding our research and development as well as new personnel and premises. This will assist us in our dual strategy of accelerating our peptide synthesiser development and sales as well as leveraging our innovative peptide technology through collaborative projects with biotechnology and pharmaceutical partners to develop new peptide therapeutics."
 |
www.bionity.com/news/e/76455 |
|
 |
|
|
© Chemie.DE Information Service GmbH http://www.bionity.com/news/e/76455 |
Seydelstr. 28 · 10117 Berlin info@chemie.de · Tel: +49 (0)30 20 45 68 - 0 |